BioMarin Pharmaceutical Inc.
105 Digital Drive
About BioMarin Pharmaceutical Inc.
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.
BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises seven approved products and multiple clinical and pre-clinical product candidates.
You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.
What makes working here unique? At BioMarin, we feel the intense tie between the work we do and the life-changing results it delivers. Our focus on rare disease gives us the rare opportunity to truly impact lives.
586 articles with BioMarin Pharmaceutical Inc.
1/24/2018Here are five possible acquisition targets to keep an eye on.
In a notice received from the FDA, the PDUFA Goal Date for pegvaliase has been extended by three months to May 28, 2018.
BioMarin Doses First Patient in Global GENEr8-1 Phase III Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
BioMarin announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec.
12/12/2017This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
BioMarin Provides 1.5 Years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th ASH Annual Meeting Concurrent With NEJM Publication
BioMarin announced today an update to its previously reported results of an open-label Phase I/II study of valoctocogene roxaparvovec.
With the 4e13 vg/kg dose, the three patients with the longest follow-up have Factor VIII activity levels that are in or near to the normal range with both median and mean values of 49%.
11/27/2017A look at the FDA's long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
BioMarin was awarded the voucher when it received approval of Brineura.
BioMarin today announced financial results for the third quarter ended September 30, 2017.
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
BioMarin updated the investment community on the Company's development portfolio at R&D Day in New York.
BioMarin To Host Third Quarter 2017 Financial Results Conference Call And Webcast On Thursday, October 26 At 4:30 P.M. ET
FDA Not Currently Planning To Hold Advisory Committee Meeting For BioMarin's Pegvaliase Biologics License Application (BLA)
BioMarin Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017
FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) And Grants Priority Review Designation
BioMarin Announces Exercise In Full Of Underwriters' Option To Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024